Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.

The Viking 74 had a blazing act to follow in replacing the Viking 72, the fastest ride in the six-decade history of the ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinically staged biopharma incorporated in 2012 and headquartered in San Diego, ... At 72 weeks, Zepbound® reported -20.2% weight loss.

Comparing Eli Lilly and Viking Therapeutics. Every market leader started somewhere, and Eli Lilly's history of innovation spans 149 years since its founding in 1876.

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. ... Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday. ...